Related Experiment Video

Updated: Aug 13, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia

M Sebestjen1, B Zegura, I Keber

  • 1Department of Angiology, Hospital of Internal Medicine, University Clinical Centre, Ljubljana, Slovenia. miran.sebestjen@trnovo.kclj.si

Journal of Internal Medicine
|February 20, 2002
PubMed

Insights

Cerivastatin improved arterial dilation more than fenofibrate in patients with combined hyperlipidaemia. Both drugs enhanced endothelium-dependent and independent arterial function, but cerivastatin showed superior effects on flow-mediated dilation.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Medical Research

Background:

  • Combined hyperlipidaemia is a significant risk factor for atherosclerosis.
  • Endothelial dysfunction plays a crucial role in the development of cardiovascular disease.
  • Statins and fibrates are commonly used to manage dyslipidemia.

Purpose of the Study:

  • To compare the efficacy of cerivastatin and fenofibrate in improving endothelial function.
  • To assess the impact of these drugs on both endothelium-dependent and independent arterial dilation.
  • To evaluate lipid-lowering effects in patients with combined hyperlipidaemia.

Main Methods:

  • Prospective, double-blind, randomized study involving 38 overweight males with combined hyperlipidaemia.
  • 12 weeks of treatment with either fenofibrate (250 mg/day) or cerivastatin (0.2-0.4 mg/day).
  • High-resolution ultrasound was used to measure flow-mediated dilation (FMD) and nitroglycerin-induced (GTN) dilation of the brachial artery.

Main Results:

  • Both cerivastatin and fenofibrate significantly improved FMD and GTN-induced dilation (P < 0.001).
  • Cerivastatin demonstrated a significantly greater improvement in FMD compared to fenofibrate (P=0.006).
  • No significant difference was observed in GTN-induced dilation between the two groups. Cerivastatin reduced LDL-C by 31%, while fenofibrate reduced triglycerides by 41%.

Conclusions:

  • Both cerivastatin and fenofibrate improve arterial dilation in overweight patients with combined hyperlipidaemia.
  • Cerivastatin showed a more pronounced effect on endothelium-dependent vasodilation (FMD) than fenofibrate.
  • The reduction in LDL-cholesterol was an independent predictor of FMD improvement.
Abstract

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...